Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2003
05/02/2003CA2411011A1 5-heteroatom-substituted pyrazoles
05/02/2003CA2411009A1 Heterocyclo-alkylsulfonyl pyrazoles
05/02/2003CA2410466A1 Hydrazinyl and nitrogen oxide pyrazoles
05/02/2003CA2410364A1 5-heterocyclo-pyrazoles
05/01/2003WO2003035883A2 Methods and compositions for inducing tumor-specific cytotoxicity
05/01/2003WO2003035872A1 Human and mammalian stem cell-derived neuronal survival polypeptides
05/01/2003WO2003035870A1 Drug for treating a carcinoma of the pancreas
05/01/2003WO2003035869A1 Use of a double-stranded ribonucleic acid for specifically inhibiting the expression of a given target gene
05/01/2003WO2003035857A1 Regulation of human nad-dependent alpha-glycerol-3-phosphate dehydrogenase
05/01/2003WO2003035855A1 Differentiation of whole bone marrow
05/01/2003WO2003035848A1 Ibc-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer
05/01/2003WO2003035847A2 Il-13 mutein proteins, antibodies, compositions, methods and uses
05/01/2003WO2003035836A2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
05/01/2003WO2003035835A2 Glycoprotein compositions
05/01/2003WO2003035688A2 Targeted thrombosis by tissue factor polypeptides
05/01/2003WO2003035687A1 Nogo receptor homologues and their use
05/01/2003WO2003035684A1 Ee3-protein family and corresponding dna sequences
05/01/2003WO2003035679A2 Molecules
05/01/2003WO2003035663A1 Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing same
05/01/2003WO2003035661A1 Derivatives of etoposide and analogs, and pharmaceutical compositions containing them
05/01/2003WO2003035660A1 Stabilization of amrubicin hydrochloride
05/01/2003WO2003035644A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003WO2003035638A1 4-imidazolin-2-one compounds
05/01/2003WO2003035635A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003WO2003035629A1 Thiopene- amd thiazolesulfonamides as antineoplastic agents
05/01/2003WO2003035627A1 Piperazine derivatives with ccr1 receptor antagonist activity
05/01/2003WO2003035626A2 Azole derivatives and pharmaceutical compositions containing them
05/01/2003WO2003035625A1 Substituted indazole compounds for the treatment of inflammation
05/01/2003WO2003035621A1 Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
05/01/2003WO2003035177A2 Optimal polymer mixtures for gastric retentive tablets
05/01/2003WO2003035137A2 Method and apparatus for dispensing inhalator medicament
05/01/2003WO2003035126A1 Process for producing biological material, drug, food, medical instrument, cell culture instrument and tissue-inducible material
05/01/2003WO2003035114A1 Radiopharmaceutical agent for the treatment of early stage cancer
05/01/2003WO2003035108A1 Immunopotentiators in thermotherapy for cancer
05/01/2003WO2003035106A1 Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
05/01/2003WO2003035105A2 A synthetic chimeric fusion protein with immuno-therapeutic uses
05/01/2003WO2003035104A2 Compositions and methods for selected tumor treatment
05/01/2003WO2003035095A1 Use of histamine to treat liver disease
05/01/2003WO2003035088A1 Kurkumin composition for the cure of large intestine polyps
05/01/2003WO2003035083A1 Drug for treating a fibrotic disease through rna interfence
05/01/2003WO2003035082A1 Drug for inhibiting expression of a target gene
05/01/2003WO2003035081A1 Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
05/01/2003WO2003035075A1 Inhibitors of human phosphatidyl-inositol 3-kinase delta
05/01/2003WO2003035065A1 Benzimidazoles and analogues and their use as protein kinases inhibitors
05/01/2003WO2003035057A1 Inhibitors of dipeptidyl peptidase iv
05/01/2003WO2003035047A2 Combinations comprising a selective cyclooxygenase-2 inhibitor
05/01/2003WO2003035043A2 Pharmaceutical formulation comprising more than 15% tamoxifen
05/01/2003WO2003035029A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
05/01/2003WO2003035012A2 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
05/01/2003WO2003035009A2 Treatment of acute myeloid leukemia with indolinone compounds
05/01/2003WO2003035008A2 Functionalized stilbene derivatives as improved vascular targeting agents
05/01/2003WO2003035007A2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
05/01/2003WO2003035004A2 Immunotherapy for reversing immune suppression
05/01/2003WO2003034997A2 Modulators of phosphoinositide 3-kinase
05/01/2003WO2003034995A2 Integrin targeting compounds
05/01/2003WO2003034903A2 Psma antibodies and protein multimers
05/01/2003WO2003018018A3 Vinorelbine compositions and methods of use
05/01/2003WO2003014063A3 Protected 3.5-dihydroxy-2.2-dimethyl-valeroamides for the synthesis of epothilone and derivatives and method for the production and use thereof
05/01/2003WO2003011873A3 Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications
05/01/2003WO2003007955A3 Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
05/01/2003WO2003005989A3 Granulates containing liposoluble substances and a process for the preparation thereof
05/01/2003WO2003002152A3 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
05/01/2003WO2002100336A3 Tissue-specific endothelial membrane proteins
05/01/2003WO2002099055A3 Cips as modifiers of the p53 pathway and method of use
05/01/2003WO2002099046A3 Spo11 as modifier of the p53 pathway and methods of use
05/01/2003WO2002098897A3 Modified antibodies to prostate-specific membrane antigen and uses thereof
05/01/2003WO2002098843A3 Certain salts of discodermolide acid, pharmaceutical compositions containing them and their use in treating tumors
05/01/2003WO2002098444A3 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
05/01/2003WO2002094840A3 Tricyclic dihydro-quinoline derivatives, method for preparing same and pharmaceutical compositions containing same
05/01/2003WO2002090352A3 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
05/01/2003WO2002083712A3 Transporters and ion channels
05/01/2003WO2002081520A3 Single chain dimeric polypeptides derived from the vegf family
05/01/2003WO2002081478A3 Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
05/01/2003WO2002076438A3 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
05/01/2003WO2002076384A3 Therapeutic compositions that alter the immune response
05/01/2003WO2002074806A3 New interferon beta-like molecules
05/01/2003WO2002074292A3 Hormone replacement therapy
05/01/2003WO2002063007A3 TIMM8b-RELATED PROTEIN
05/01/2003WO2002051406A9 Methods for inducing apoptosis and inhibiting proliferation in cancer cells
05/01/2003WO2002048165A3 Antiviral agents for treatment of flaviviridae infections
05/01/2003WO2002048148A3 Pyrazolopyridine derivatives
05/01/2003WO2002039995A3 Combination therapy for estrogen-dependent disorders
05/01/2003WO2002036783A3 Regulation of human histone deacetylase
05/01/2003WO2002034282A3 Mammary secreted protein 36 (msp36) for cancer treatment and diagnosis
05/01/2003WO2002022851A3 Novel tumor-associated marker
05/01/2003WO2002005830A3 Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof
05/01/2003WO2001079291A3 Secreted proteins
05/01/2003WO2000071564A3 Isolated nucleic acids of the p-hyde family, p-hyde proteins, and methods of inducing susceptibility to induction of cell death in cancer
05/01/2003US20030083504 N- (4-carbamimidoyl-phenyl) -glycine derivatives
05/01/2003US20030083500 Imidazonaphthyridines
05/01/2003US20030083494 Porphyrins containing multiple carborane cages which selectively accumulate in neoplastic tissue within the irradiation volume; anticancer agents
05/01/2003US20030083481 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of prostate cancer
05/01/2003US20030083465 Protein for use in treatment and prevention of angiogenesis
05/01/2003US20030083374 NAALADase inhibitors useful as pharmaceutical compounds and compositions
05/01/2003US20030083370 Administering 5-amino-2,2-dimethyl-6-(3'-(R,S)amino-4'-hydroxy-butan-1-one)-2,3-dihydro-4H-1-benzopyran-4-one (FC101) for treatment of neovascularization and cellular proliferation; antitumor agents; veterinary medicine
05/01/2003US20030083368 Cancer cell implantation inhibitors
05/01/2003US20030083367 Diesterifying paclitaxel with hexanoic acid; antitumor agents
05/01/2003US20030083366 Combination chemotherapy
05/01/2003US20030083364 3-Substituted-3-(substitutedsulfonyl or sulfanyl)pyrroldine-2,5-diones useful for inhibition of farnesyl-protein transferase
05/01/2003US20030083363 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
1 ... 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 ... 2211